NCT07113808 Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China
| NCT ID | NCT07113808 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Children's Hospital of Zhejiang University School of Medicine |
| Condition | Abdominal Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 108 participants |
| Start Date | 2024-09-10 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 108 participants in total. It began in 2024-09-10 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the application of intravenous contrast-enhanced ultrasound examination in children with intra-abdominal diseases that require clear diagnoses. The main questions it aims to answer are: * Is intravenous contrast-enhanced ultrasound helpful for the diagnosis of intra-abdominal diseases in children? * What medical problems do participants have when participating in intravenous contrast-enhanced ultrasound examination? * How can ultrasound doctors conduct intravenous contrast-enhanced ultrasound examinations in a standardized manner? Researchers will performing intravenous contrast-enhanced ultrasound examinations on participants and collecting research subjects to establish a multicenter clinical data database. Participants will: * Perform abdominal ultrasound examination to assess the condition. * At least conduct one intravenous contrast-enhanced ultrasound examination. Based on the result of the contrast examination, decide whether to conduct another examination. * Keep a diary of their symptoms and therapeutic process in 30 days.
Eligibility Criteria
Inclusion Criteria: 1. Age 29 days to 18 years old; 2. The clinical diagnosis was abdominal space-occupying lesions, blunt abdominal trauma, ascites of unknown cause, and children with suspected abdominal disease but other examinations could not identify the cause. Exclusion Criteria: 1. Allergic to sulfur hexafluoride or other components; 2. Heart disease with right-to-left shunt/severe pulmonary hypertension /uncontrolled systemic hypertension/respiratory failure/heart failure/severe arrhythmia; 3. Electrocardiogram, echocardiography or clinical manifestations of myocardial ischemia; 4. Patients with severe blood system diseases or infectious diseases; 5. Hypercoagulable state and recent history of thrombosis; 6. Severe hepatic and renal insufficiency; 7. Patients with respiratory tract infection or congenital respiratory malformation.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07113808 clinical trial?
This trial is open to participants of all sexes, aged 29 Days or older, up to 18 Years, studying Abdominal Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07113808 currently recruiting?
Yes, NCT07113808 is actively recruiting participants. Contact the research team at 6195005@zju.edu.cn for enrollment information.
Where is the NCT07113808 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT07113808 clinical trial?
NCT07113808 is sponsored by The Children's Hospital of Zhejiang University School of Medicine. The trial plans to enroll 108 participants.